Stockscreener 앱 받기
30.10
0.73%
-0.22
전일 마감가:
$30.32
열려 있는:
$30.3
하루 거래량:
353.51K
Relative Volume:
0.55
시가총액:
$1.68B
수익:
$681.88M
순이익/손실:
$122.63M
주가수익비율:
14.27
EPS:
2.11
순현금흐름:
$220.18M
1주 성능:
+2.52%
1개월 성능:
+2.87%
6개월 성능:
-9.91%
1년 성능:
-4.66%
1일 변동 폭
$29.88
$30.50
1주일 범위
$28.64
$30.61
52주 변동 폭
$26.47
$41.61
하모니 바이오 Stock (HRMY) Company Profile
명칭
Harmony Biosciences Holdings Inc
전화
(484) 539-9800
주소
630 W GERMANTOWN PIKE, PLYMOUTH MEETING
HRMY을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
HRMY
Harmony Biosciences Holdings Inc
|
30.08 | 1.68B | 681.88M | 122.63M | 220.18M | 2.11 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.99 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
606.73 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
653.95 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
271.21 | 32.98B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
255.09 | 26.89B | 3.81B | -644.79M | -669.77M | -6.24 |
하모니 바이오 Stock (HRMY) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-11 | 개시 | Deutsche Bank | Buy |
| 2024-12-17 | 개시 | H.C. Wainwright | Buy |
| 2024-10-10 | 재개 | Raymond James | Outperform |
| 2024-09-10 | 개시 | UBS | Buy |
| 2024-06-21 | 개시 | Citigroup | Buy |
| 2024-01-02 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2023-09-25 | 다운그레이드 | Goldman | Neutral → Sell |
| 2023-09-07 | 개시 | Berenberg | Buy |
| 2023-04-20 | 개시 | BofA Securities | Neutral |
| 2022-10-14 | 업그레이드 | Janney | Neutral → Buy |
| 2022-10-14 | 업그레이드 | Jefferies | Hold → Buy |
| 2022-08-03 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-07-13 | 다운그레이드 | Goldman | Buy → Neutral |
| 2022-07-07 | 개시 | Mizuho | Buy |
| 2022-04-14 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-12-01 | 개시 | Oppenheimer | Outperform |
| 2021-11-04 | 개시 | Raymond James | Outperform |
| 2021-09-23 | 개시 | Needham | Buy |
| 2021-03-29 | 업그레이드 | Goldman | Neutral → Buy |
| 2020-09-14 | 개시 | Goldman | Neutral |
| 2020-09-14 | 개시 | Jefferies | Buy |
| 2020-09-14 | 개시 | Piper Sandler | Overweight |
모두보기
하모니 바이오 주식(HRMY)의 최신 뉴스
Harmony Biosciences Holdings Inc (HRMY) Q1 2025 Earnings Report Preview: What to Look For - GuruFocus
Raymond James Financial Inc. Makes New $1.30 Million Investment in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) - Defense World
Wells Fargo & Company MN Reduces Holdings in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) - Defense World
Harmony Biosciences Holdings Inc expected to post earnings of 59 cents a shareEarnings Preview - TradingView
(HRMY) Trading Signals - news.stocktradersdaily.com
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Receives Average Rating of “Buy” from Analysts - Defense World
Why Harmony Biosciences (HRMY) Could Beat Earnings Estimates Again - Yahoo Finance
H.C. Wainwright maintains $70 target on Harmony Biosciences stock By Investing.com - Investing.com India
Harmony Biosciences to Report First Quarter 2025 Financial Results on May 6, 2025 - BioSpace
H.C. Wainwright maintains $70 target on Harmony Biosciences stock - Investing.com Australia
Harmony Biosciences to Report First Quarter 2025 Financial Resul - GuruFocus
H.C. Wainwright Reiterates Buy Rating on Harmony Biosciences Holdings Inc. (HRMY) - StreetInsider
UBS Adjusts Price Target for Harmony Biosciences (HRMY) | HRMY S - GuruFocus
UBS Adjusts Price Target on Harmony Biosciences to $48 From $55, Maintains Buy Rating - marketscreener.com
Press Release Distribution & PR Platform - ACCESS Newswire
Harmony Biosciences (HRMY) Projected to Post Earnings on Tuesday - Defense World
First Week of June 20th Options Trading For Harmony Biosciences Holdings (HRMY) - Nasdaq
Is Weakness In Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects? - simplywall.st
BofA Cuts Price Target on Harmony Biosciences to $32 From $33 - marketscreener.com
Harmony Biosciences (HRMY) Faces Revised Price Target Amid Q1 Ch - GuruFocus
Invesco Ltd. Raises Stake in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) - Defense World
JAZZ vs. HRMY: Which Neuroscience Drugmaker Is the Stronger Play? - Zacks Investment Research
Harmony Biosciences Holdings, Inc. (HRMY) Investigation: Bronstei - NatLawReview.com
Russell Investments Group Ltd. Has $1.60 Million Stock Position in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) - Defense World
Harmony Biosciences Presents Positive Data on ZYN002 for Fragile X Syndrome - MSN
Geode Capital Management LLC Has $31.08 Million Stock Holdings in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) - Defense World
(HRMY) Technical Data - news.stocktradersdaily.com
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Shares Bought by JPMorgan Chase & Co. - Defense World
Franklin Resources Inc. Has $1.10 Million Stock Position in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) - Defense World
Lobbying Update: $45,000 of HARMONY BIOSCIENCES lobbying was just disclosed - Nasdaq
Harmony Biosciences Appoints Ron Philip to Board of Directors - MSN
Harmony Biosciences (NASDAQ:HRMY) Earns “Buy” Rating from HC Wainwright - Defense World
Breaking Down Harmony Biosciences Hldgs: 13 Analysts Share Their Views - Benzinga
Harmony Biosciences Presents Promising Open-Label Extension Data of ZYN002 in Fragile X Syndrome - BioSpace
Oppenheimer maintains Harmony Biosciences Outperform rating By Investing.com - Investing.com South Africa
Developmental and Epileptic Encephalopathies Market to Observe Stunning Growth During the Study Period (2020–2034) | DelveInsight - GlobeNewswire Inc.
Oppenheimer on Harmony Biosciences (HRMY): 'we remain pleased with WAKIX's 4Q24 performance' - StreetInsider
Bronstein, Gewirtz & Grossman, LLC Is Investigating Harmony Biosciences Holdings, Inc. (HRMY) And Encourages Shareholders to Connect - markets.businessinsider.com
Harmony Biosciences reports progress in Fragile X syndrome gel treatment - Investing.com
Harmony Biosciences reports progress in Fragile X syndrome gel treatment By Investing.com - Investing.com India
HRMY stock touches 52-week low at $27.87 amid market shifts By Investing.com - Investing.com South Africa
HRMY stock touches 52-week low at $27.87 amid market shifts - Investing.com India
Corebridge Financial Inc. Raises Stock Holdings in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) - Defense World
Vanguard Group Inc. Has $162.88 Million Stock Holdings in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) - The AM Reporter
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Stock Holdings Increased by Vanguard Group Inc. - Defense World
Arrowstreet Capital Limited Partnership Has $10.21 Million Stock Position in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) - The AM Reporter
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Given Average Rating of “Buy” by Analysts - The AM Reporter
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Given Consensus Recommendation of “Buy” by Analysts - Defense World
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Harmony Biosciences Holdings, Inc. (HRMY) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Harmony Biosciences Holdings, Inc. (HRMY) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - markets.businessinsider.com
하모니 바이오 (HRMY) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.27%
0.30%
자본화:
|
볼륨(24시간):